• Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

FDA Approves Combination Drug for Patients with Advanced Colorectal Cancer

October 14, 2015, by NCI Staff

Colon cancer cells

Human colon cancer cells.

Credit: National Cancer Institute

On September 22, the Food and Drug Administration (FDA) approved a tablet that combines the drugs trifluridine and tipiracil hydrochloride (Lonsurf®) to treat patients with metastatic colorectal cancer whose disease progressed after standard treatments. The drug combination was previously known as TAS-102.

The safety and efficacy of trifluridine and tipiracil was tested in a randomized phase III clinical trial of 800 primarily Japanese patients with metastatic colorectal cancer, the results of which were published earlier this year in the New England Journal of Medicine.

Median overall survival in patients treated with Lonsurf was 7.1 months compared with 5.3 months for patients who received a placebo.

“The trifluridine and tipiracil combination offers a novel option for patients with advanced colorectal cancer who are not responding to other therapies,” said Jo Anne Zujewski, M.D., of NCI’s Cancer Therapy Evaluation Program, who was not involved in the study.

The most significant adverse reactions among patients receiving trifluridine and tipiracil were neutropenia, leukopenia, and febrile neutropenia. Because of the potential for these adverse reactions, the drug’s label warns that patients with kidney problems should not take this drug.

< Older Post

Progress against Cancer: The Role of Basic Science

Newer Post >

New on NCI’s Websites

Most text on the National Cancer Institute website may be reproduced or reused freely. The National Cancer Institute should be credited as the source and a link to this page included, e.g., “FDA Approves Combination Drug for Patients with Advanced Colorectal Cancer was originally published by the National Cancer Institute.”

Please note that blog posts that are written by individuals from outside the government may be owned by the writer, and graphics may be owned by their creator. In such cases, it is necessary to contact the writer, artists, or publisher to obtain permission for reuse.

We welcome your comments on this post. All comments must follow our comment policy.

blog comments powered by Disqus